Skip to main content
ANAPTYSBIO, INC logo

ANAPTYSBIO, INC — Investor Relations & Filings

Ticker · ANAB ISIN · US0327241065 LEI · 529900HH4WQT03IG1A12 US Professional, scientific and technical activities
Open in API
Filings indexed 636 across all filing types
Latest filing 2017-03-08 Earnings Release
Country US United States of America
Listing US ANAB

About ANAPTYSBIO, INC

https://www.anaptysbio.com/

AnaptysBio, Inc. is a clinical-stage biotechnology company that focuses on the discovery and development of innovative immunology therapeutics. The company specializes in advancing immune cell-modulating antibodies designed to treat autoimmune and inflammatory diseases. Its therapeutic candidates target key pathways in the immune system to address significant unmet medical needs for various patient populations.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filing with the SEC, dated March 8, 2017, reporting the issuance of a press release announcing financial results for the year ended December 31, 2016. The text explicitly states that the press release is attached as Exhibit 99.01 and that the information is not filed for purposes of certain securities laws, indicating this is an announcement of financial results rather than the full financial report itself. The document length is 3362 characters, which is relatively short and consistent with an announcement rather than a full earnings release or annual report. The content corresponds to an Earnings Release announcement within an 8-K filing. Therefore, the best classification is Earnings Release (ER).
2017-03-08 English
FORM 8-K
Remuneration Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 24, 2017, reporting the approval of 2016 annual bonuses for named executive officers and providing a revised 2016 Summary Compensation Table. The content focuses on executive compensation details and changes in compensation disclosures. There is no indication of a full annual report, audit report, earnings release, or other financial statements. The primary subject is compensation information for executives, which aligns with Remuneration Information filings. The document is not merely an announcement or certification but contains substantive compensation data. Therefore, the appropriate classification is Remuneration Information (DEF 14A).
2017-03-02 English
FORM 4 SUBMISSION
Director's Dealing
2017-03-01 English
FORM 4 SUBMISSION
Director's Dealing
2017-03-01 English
FORM 4 SUBMISSION
Director's Dealing
2017-03-01 English
FORM 4 SUBMISSION
Director's Dealing
2017-03-01 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.